GlassScriptPhysician profile
Michael Glenn Carlson
NPI 1386639219
$381,306.31
in general payments reported to CMS, 2019-2025
65 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $74K · 2021: $68K · 2022: $69K · 2023: $43K · 2024: $13K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $14K · Travel and Lodging: $3,296 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $66,155.19 |
| Food and Beverage | $13,656.22 |
| Travel and Lodging | $3,296.48 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $191,927.48 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Amgen INC. | $58,214.29 | 2019-2025 | Evenity, Tepezza, Repatha |
| Lilly USA, LLC | $36,314.02 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30,418.41 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $28,266.77 | 2019-2024 | Farxiga |
| Abbvie INC. | $19,447.03 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $3,271.60 | 2019-2025 | Korlym |
| Abbott Laboratories | $2,182.89 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Sanofi-Aventis U.S. LLC | $1,119.14 | 2019-2025 | |
| Beta Bionics, INC. | $941.77 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $877.25 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Mannkind Corporation | $673.14 | 2019-2025 | Afrezza |
| Insulet Corporation | $559.95 | 2019-2025 | Omnipod |
| Ibsa Pharma INC. | $528.68 | 2020-2025 | Licart, Tirosint, Tirosint |
| Medtronic, INC. | $513.65 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.